GH Research’s (GHRS) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of GH Research (NASDAQ:GHRS) in a research note released on Wednesday,Benzinga reports. They currently have a $40.00 target price on the stock.

Several other equities research analysts also recently commented on GHRS. Canaccord Genuity Group reduced their target price on GH Research from $31.00 to $28.00 and set a “buy” rating for the company in a report on Monday. JMP Securities reaffirmed a “market outperform” rating and set a $39.00 price objective on shares of GH Research in a research note on Wednesday, September 4th.

GH Research Stock Up 13.9 %

Shares of GHRS opened at $10.95 on Wednesday. The firm’s 50 day moving average is $7.87 and its 200-day moving average is $10.33. GH Research has a 12-month low of $5.05 and a 12-month high of $14.99.

GH Research (NASDAQ:GHRS) last issued its earnings results on Tuesday, September 3rd. The company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.03. On average, research analysts anticipate that GH Research will post -0.78 EPS for the current year.

Institutional Trading of GH Research

A hedge fund recently raised its stake in GH Research stock. Lynx1 Capital Management LP increased its holdings in GH Research PLC (NASDAQ:GHRS) by 19.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,966,726 shares of the company’s stock after acquiring an additional 656,163 shares during the period. GH Research comprises about 16.7% of Lynx1 Capital Management LP’s holdings, making the stock its 3rd largest holding. Lynx1 Capital Management LP owned approximately 7.62% of GH Research worth $46,252,000 at the end of the most recent quarter. 56.90% of the stock is currently owned by institutional investors and hedge funds.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).